PSMA peptide-pulsed autologous PBMC

PSA (in this specific clinical context) refers to an investigational autologous cellular immunotherapy developed by the University of Chicago for the treatment of metastatic hormone-refractory prostate cancer. The therapy involves harvesting a patient's peripheral blood mononuclear cells (PBMCs) and pulsing them ex vivo with peptides derived from the Prostate-Specific Membrane Antigen (PSMA). These antigen-loaded cells are then re-infused into the patient, typically in conjunction with recombinant human interleukin-12 (rhIL-12) as an adjuvant, to induce a targeted T-cell immune response against PSMA-expressing tumor cells. This approach was evaluated in a Phase II clinical trial (NCT00015977) but has not proceeded to regulatory approval.

Other names

PSMA peptide vaccinePSMA peptide-pulsed autologous peripheral blood mononuclear cells